Geno Germano is Group President of Pfizer’s Global Innovative Pharma Business (GIP) – one of the company’s three new global operating units. In this role, Germano leads an innovative products group focused on core assets within several therapeutic areas, including inflammation, cardiovascular and metabolic, neuroscience and pain, rare diseases, and women’s and men’s health. The GIPB's current portfolio includes more than 24 medicines and a pipeline full of new innovative assets.
Previously, Germano served as President and General Manager of Pfizer’s Specialty Care and Oncology business units.
Germano joined Pfizer from Wyeth Pharmaceuticals, where he served as President of the U.S. and Pharmaceutical business units. In this role, he was responsible for the units U.S. - based Pharmaceuticals, Biologics and Vaccines businesses. In addition, he led the global strategy for the Pharmaceutical and Institutional business units for major products in neuroscience, gastroenterology, women's health, infectious diseases and immunology.
In his more than 25 years in the pharmaceutical industry, Germano has held diverse positions, including Executive Vice President and General Manager for Wyeth Global Vaccines; Managing Director, Wyeth Australia and New Zealand; and Executive Vice President and General Manager of the Pharmaceutical business unit. He led numerous key product launches in primary and specialty care therapeutic areas, including gastroenterology, arthritis, infectious diseases, hemophilia, transplantation and oncology. Prior to joining Wyeth, Germano held leadership positions at several Johnson & Johnson companies.
Germano currently serves on the Advisory Board of the Healthcare Businesswomen's Association, is a member of the Board of the Biotechnology Industry Organization (BIO), and is a Trustee of the Albany College of Pharmacy, where he received his Bachelor of Science degree in Pharmacy in 1983.